腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）接种后噬血细胞性淋巴组织细胞增生症：罕见病例。

Haemophagocytic lymphohistiocytosis post-ChAdOx1 nCoV-19 vaccine: A rare case.

机构信息

Department of Pulmonary, Critical Care and Sleep Medicine, Army Institute of Cardiothoracic Sciences, Pune, Maharashtra, India.

Department of Pathology, Army Institute of Cardiothoracic Sciences, Pune, Maharashtra, India.

出版信息

Natl Med J India. 2024 Mar-Apr;37(2):90-92. doi: 10.25259/NMJI_MS_466_21.

DOI:10.25259/NMJI_MS_466_21

PMID:39222526

Abstract

The severe acute respiratory syndrome coronavirus 2 pandemic started in December 2019, spread like wildfire and took an immense toll on human life. ChAdOx1 nCoV-19 vaccine was used worldwide for the prevention of Covid-19. Covid-19 has been implicated in the causation of severe haemophagocytic lymphohistiocytosis (HLH) syndrome. However, the same has not been reported with ChAdOx1 nCoV-19 vaccine in the literature. We report a young man who developed secondary HLH post-ChAdOx1 nCoV-19 vaccination.

摘要

严重急性呼吸综合征冠状病毒 2 型大流行始于 2019 年 12 月，迅速蔓延，并对人类生命造成了巨大损失。ChAdOx1 nCoV-19 疫苗在全球范围内用于预防新冠肺炎。新冠肺炎已被认为与严重噬血细胞性淋巴组织细胞增生症（HLH）综合征的发生有关。然而，文献中尚未报道 ChAdOx1 nCoV-19 疫苗与此相关。我们报告了一名年轻男性在接种 ChAdOx1 nCoV-19 疫苗后发生继发性 HLH。